Patents by Inventor Ka Yin Kwong

Ka Yin Kwong has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Fully human anti-human NKG2D monoclonal antibodies
    Patent number: 9273136
    Abstract: The invention relates to isolated fully human monoclonal antibodies having specificity for human NKG2D and compositions thereof. The invention further relates to methods for using such antibodies in treating diseases or conditions such as cancer, autoimmune disease, or infectious disease.
    Type: Grant
    Filed: July 31, 2009
    Date of Patent: March 1, 2016
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Christoph Rader, Ka Yin Kwong
  • FULLY HUMAN ANTI-HUMAN NKG2D MONOCLONAL ANTIBODIES
    Publication number: 20110150870
    Abstract: The invention relates to isolated fully human monoclonal antibodies having specificity for human NKG2D and compositions thereof. The invention further relates to methods for using such antibodies in treating diseases or conditions such as cancer, autoimmune disease, or infectious disease.
    Type: Application
    Filed: July 31, 2009
    Publication date: June 23, 2011
    Applicant: THE UNITED STATES OF AMERICA, AS REPRESENTED BY TH
    Inventors: Christoph Rader, Ka Yin Kwong
  • Bipartite T-cell factor (Tcf)-responsive promoter
    Publication number: 20030228285
    Abstract: The present invention is directed to methods and compositions for cancer therapy, particularly cancers resulting from a defective Wnt/&bgr;-catenin signaling pathway. In specific embodiments, a T-cell factor (Tcf)-responsive promoter regulating expression of a therapeutic gene is administered to an individual having the cancer. In a specific embodiment, the Tcf-responsive promoter comprises a minimal CMV promoter and is present on an adenovirus vector. The promoter regulates expression of a therapeutic gene.
    Type: Application
    Filed: May 5, 2003
    Publication date: December 11, 2003
    Inventors: Mien-Chie Hung, Ka Yin Kwong, Yiyu Zou
  • Antitumor activity of Bok
    Publication number: 20030139344
    Abstract: The present invention is directed to the pro-apoptotic bok gene product that provides antitumor activity, particularly through induction of apoptosis. In some embodiments of the present invention, Bok is utilized for ovarian cancer, among others, and the composition can be delivered by either viral or non-viral delivery methods.
    Type: Application
    Filed: November 19, 2002
    Publication date: July 24, 2003
    Inventors: Mien-Chie Hung, Yiyu Zou, Ka Yin Kwong, Geoffrey Bartholomeusz